Investors purchased shares of Gilead Sciences Inc. (NASDAQ:GILD) on weakness during trading on Friday. $357.33 million flowed into the stock on the tick-up and $281.22 million flowed out of the stock on the tick-down, for a money net flow of $76.11 million into the stock. Of all equities tracked, Gilead Sciences had the 13th highest net in-flow for the day. Gilead Sciences traded down ($1.77) for the day and closed at $79.47

GILD has been the topic of a number of recent research reports. Leerink Swann reissued an “outperform” rating and set a $127.00 target price on shares of Gilead Sciences in a research report on Friday, April 1st. Morgan Stanley reissued a “hold” rating and set a $111.00 target price on shares of Gilead Sciences in a report on Friday, April 1st. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $104.96 price target for the company. in a research report on Monday, April 4th. BMO Capital Markets assumed coverage on shares of Gilead Sciences in a research report on Tuesday, April 5th. They set a “market perform” rating and a $102.00 price target for the company. Finally, Jefferies Group increased their target price on shares of Gilead Sciences to $101.00 and gave the company a “hold” rating in a research report on Wednesday, April 6th. Eleven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $107.37.

The stock has a market capitalization of $105.77 billion and a PE ratio of 6.97. The company has a 50-day moving average of $84.02 and a 200 day moving average of $88.46.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. The firm earned $7.78 billion during the quarter, compared to the consensus estimate of $7.80 billion. The company’s revenue was down 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.15 EPS. Equities analysts predict that Gilead Sciences Inc. will post $11.79 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.37%. The ex-dividend date is Wednesday, September 14th.

In related news, CEO John F. Milligan sold 112,000 shares of the business’s stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $87.71, for a total transaction of $9,823,520.00. Following the transaction, the chief executive officer now directly owns 1,170,963 shares of the company’s stock, valued at approximately $102,705,164.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul Rutherford Carter sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $88.72, for a total value of $177,440.00. Following the transaction, the executive vice president now directly owns 62,939 shares in the company, valued at $5,583,948.08. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently modified their holdings of the company. Legacy Capital Partners Inc. raised its position in shares of Gilead Sciences by 0.3% in the fourth quarter. Legacy Capital Partners Inc. now owns 34,648 shares of the biopharmaceutical company’s stock worth $3,507,000 after buying an additional 103 shares in the last quarter. Westbourne Investment Advisors Inc. raised its position in shares of Gilead Sciences by 0.3% in the fourth quarter. Westbourne Investment Advisors Inc. now owns 43,521 shares of the biopharmaceutical company’s stock worth $4,404,000 after buying an additional 118 shares in the last quarter. Pitcairn Co. raised its position in shares of Gilead Sciences by 1.2% in the fourth quarter. Pitcairn Co. now owns 12,733 shares of the biopharmaceutical company’s stock worth $1,289,000 after buying an additional 147 shares in the last quarter. Kornitzer Capital Management Inc. KS raised its position in shares of Gilead Sciences by 0.7% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 21,430 shares of the biopharmaceutical company’s stock worth $2,169,000 after buying an additional 150 shares in the last quarter. Finally, Brave Asset Management Inc raised its position in shares of Gilead Sciences by 0.6% in the fourth quarter. Brave Asset Management Inc now owns 24,430 shares of the biopharmaceutical company’s stock worth $2,472,000 after buying an additional 150 shares in the last quarter.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.